STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir (STO:MVIRB):
The data from a small explorative study will be presented tomorrow at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy. These are the first data to be presented on the use of TMC435350 in Hepatitis C patients. There will also be a poster presentation under the title; “Once-daily regimens of the HCV NS3/4A-protease inhibitor TMC435350 are predicted to provide therapeutic exposure in plasma and liver”.
